Main Article Content

Hafeez Ullah
Sonia Tariq
Zainab lanjar
Ishtiaq Hussain
Asim Shamim
Noorahman Noori
Sadia Hakeem
Erum Bughio
Muhammad Mohsen Rahimoon
Muhammad Arif Rizwan
Habibullah Janyaro


ANLN, LIHC, Biomarker, Prognosis


The role of Anillin Actin Binding protein (ANLN) in Liver Hepatocellular Carcinoma (LIHC) is investigated through comprehensive expression and methylation analyses, genetic mutation inquiry, and prognostic assessment. Utilizing the UALAN database, ANLN expression is found significantly elevated in LIHC samples compared to normal controls, suggesting its regulatory involvement in LIHC proliferation. Further examination based on different parameters such as cancer stages, patient demographics, and promoter methylation levels reveals consistent overexpression of ANLN across diverse conditions, emphasizing its pivotal role in LIHC pathogenesis. Interestingly, promoter hypomethylation of ANLN is observed in LIHC samples compared to normal controls, indicating a negative correlation between ANLN expression and promoter methylation, with therapeutic implications. Genetic mutation analysis via cBioPortal identifies a minimal proportion of ANLN mutations in LIHC, predominantly amplifications and missense mutations, indicating their basal significance in ANLN dysregulation within LIHC. Prognostic assessment utilizing KM plotter demonstrates a significant correlation between ANLN overexpression and decreased overall survival rates in LIHC patients, suggesting ANLN's potential as a prognostic biomarker for disease progression and patient outcome prediction. Collectively, these findings underscore the crucial involvement of ANLN in LIHC progression and development, providing insights into its potential as a therapeutic target and prognostic indicator in the clinical management of LIHC. Further exploration of ANLN's molecular mechanisms and its interplay within the LIHC microenvironment may unveil novel avenues for targeted therapy and precision medicine approaches in combating this challenging disease.

Abstract 64 | PDF Downloads 20


1. Hameed Y, Ejaz S. TP53 lacks tetramerization and N-terminal domains due to novel inactivating mutations detected in leukemia patients. Journal of Cancer Research and Therapeutics. 2021;17(4):931-7.
2. Ahmad M, Khan M, Asif R, Sial N, Abid U, Shamim T, et al. Expression characteristics and significant diagnostic and prognostic values of ANLN in human cancers. International Journal of General Medicine. 2022:1957-72.
3. Khan M, Hameed Y. Discovery of novel six genes-based cervical cancer-associated biomarkers that are capable to break the heterogeneity barrier and applicable at the global level. Journal of Cancer Research and Therapeutics. 9000.
4. Usman M, Hameed Y, Ahmad M. Does human papillomavirus cause human colorectal cancer? Applying Bradford Hill criteria postulates. ecancermedicalscience. 2020;14.
5. Xu W, Li H, Hameed Y, Abdel-Maksoud MA, Almutairi SM, Mubarak A, et al. Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma. Oncology Research. 2023;31(5):819.
6. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029-30.
7. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
8. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016;66(2):115-32.
9. Wei W, Zeng H, Zheng R, Zhang S, An L, Chen R, et al. Cancer registration in China and its role in cancer prevention and control. The Lancet Oncology. 2020;21(7):e342-e9.
10. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(S1):4-13.
11. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87-108.
12. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2019;394(10204):1145-58.
13. Asafo-Agyei KO SH. Hepatocellular Carcinoma. StatPearls. 2023 Jun 12.
14. Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer. 2020;9(6):682-720.
15. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86.
16. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007 Aug;5(8):938-45, 45.e1-4.
17. Hameed A, Condò C, Tauseef I, Idrees M, Ghazanfar S, Farid A, et al. Isolation and Characterization of a Cholesterol-Lowering Bacteria from Bubalus bubalis Raw Milk. Fermentation. 8 (4): 163. 2022.
18. Usman M, Hameed Y. GNB1, a novel diagnostic and prognostic potential biomarker of head and neck and liver hepatocellular carcinoma. Journal of Cancer Research and Therapeutics. 9000.
19. Identification of Key Biomarkers for the Future Applications in Diagnostics and Targeted Therapy of Colorectal Cancer. Current Molecular Medicine. 2022.
20. Usman M, Hameed Y, Ahmad M. Does epstein–barr virus participate in the development of breast cancer? A brief and critical review with molecular evidences. Biomedical and Biotechnology Research Journal (BBRJ). 2020;4(4):285-92.
21. Gbadegesin RA, Hall G, Adeyemo A, Hanke N, Tossidou I, Burchette J, et al. Mutations in the gene that encodes the F-actin binding protein anillin cause FSGS. J Am Soc Nephrol. 2014 Sep;25(9):1991-2002.
22. Hall PA, Todd CB, Hyland PL, McDade SS, Grabsch H, Dattani M, et al. The septin-binding protein anillin is overexpressed in diverse human tumors. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6780-6.
23. Lian YF, Huang YL, Wang JL, Deng MH, Xia TL, Zeng MS, et al. Anillin is required for tumor growth and regulated by miR-15a/miR-16-1 in HBV-related hepatocellular carcinoma. Aging (Albany NY). 2018 Aug 9;10(8):1884-901.
24. Zeng S, Yu X, Ma C, Song R, Zhang Z, Zi X, et al. Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma. Sci Rep. 2017 Jun 9;7(1):3151.
25. Zeng S, Yu X, Ma C, Song R, Zhang Z, Zi X, et al. Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma. Scientific Reports. 2017;7(1):3151.
26. Hall PA, Todd CB, Hyland PL, McDade SS, Grabsch H, Dattani M, et al. The septin-binding protein anillin is overexpressed in diverse human tumors. Clinical cancer research. 2005;11(19):6780-6.
27. Magnusson K, Gremel G, Rydén L, Pontén V, Uhlén M, Dimberg A, et al. ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer. BMC cancer. 2016;16:1-13.
28. Wang Z, Cao S, Morris JS, Ahn J, Liu R, Tyekucheva S, et al. Transcriptome deconvolution of heterogeneous tumor samples with immune infiltration. IScience. 2018;9:451-60.
29. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649-58.
30. Hameed Y. Decoding the significant diagnostic and prognostic importance of maternal embryonic leucine zipper kinase in human cancers through deep integrative analyses. Journal of Cancer Research and Therapeutics. 2023;19(7):1852-64.
31. Maciejczyk A, Szelachowska J, Czapiga B, Matkowski R, Hałoń A, Györffy B, et al. Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. J Histochem Cytochem. 2013 May;61(5):330-9.
32. Lánczky A, Győrffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. Journal of medical Internet research. 2021;23(7):e27633.
33. Karamat U, Ejaz S, Hameed Y. In silico-analysis of the multi-omics data identified the ataxia telangiectasia mutated gene as a potential biomarker of breast invasive carcinoma. Genetic Testing and Molecular Biomarkers. 2021;25(4):263-75.
34. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012;2(5):401-4.
35. Dong Y, Wu X, Xu C, Hameed Y, Abdel-Maksoud MA, Almanaa TN, et al. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures. Aging. 2024;16(3):2591-616.
36. Hu H, Umair M, Khan SA, Sani AI, Iqbal S, Khalid F, et al. CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology. American Journal of Translational Research. 2024;16(2):432.
37. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
38. Abdel-Maksoud MA, Ullah S, Nadeem A, Shaikh A, Zia MK, Zakri AM, et al. Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis. American Journal of Translational Research. 2024;16(1):63.
39. Luo M, Rehman A, Haque S, Izhar S, Perveen F, Haris M, et al. Thorough examination of the potential biological implications of the cuproptosis-related gene LIPT2 in the prognosis and immunotherapy in pan-cancer. American Journal of Translational Research. 2024;16(3):940.
40. Piekny AJ, Maddox AS. The myriad roles of Anillin during cytokinesis. Semin Cell Dev Biol. 2010 Dec;21(9):881-91.
41. Ahmad M KM, Asif R, Sial N, Abid U, Shamim T, Hameed Z, Iqbal MJ, Sarfraz U, Saeed H, Asghar Z, Akram M, Ullah Q, Younas QUA, Rauf L, Hadi A, Maryam S, Hameed Y, Khan MR, Tariq E, Saeed S. Expression Characteristics and Significant Diagnostic and Prognostic Values of ANLN in Human Cancers. Int J Gen Med. 2022
42. Yasir M, Nawaz A, Ghazanfar S, Okla MK, Chaudhary A, Al WH, et al. Anti-bacterial activity of essential oils against multidrug-resistant foodborne pathogens isolated from raw milk. Braz J Biol. 2022;84:e259449.
43. Mao J, Huang X, Okla MK, Abdel-Maksoud MA, Mubarak A, Hameed Z, et al. Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review. Comput Math Methods Med. 2022;2022:1721526.
44. Usman M, Hameed Y, Ahmad M, Jalil Ur R, Ahmed H, Hussain MS, et al. Breast Cancer Risk and Human Papillomavirus Infection: A Bradford Hill Criteria Based Evaluation. Infect Disord Drug Targets. 2022;22(4):e200122200389.

Most read articles by the same author(s)

1 2 > >>